KROS240621C90000
- 3.00
- 0.000.00%
Keros Therapeutics Newsroom
Analyst Sees Keros Therapeutics As Next Acceleron, Set For Major Biotech Growth
Oppenheimer initiated coverage on Keros Therapeutics Inc (NASDAQ:KROS), a clinical-stage biopharmaceutical company that develops and commercializes novel therapeutics for disorders linked to dysfuncti
Small-cap, Buy-rated Stocks With Positive Estimate Revision Factors - BofA
Oppenheimer Maintains Keros Therapeutics(KROS.US) With Buy Rating, Raises Target Price to $102
Wedbush analyst Andreas Argyrides maintains $Keros Therapeutics(KROS.US)$ with a buy rating, and adjusts the target price from $86 to $102.According to TipRanks data, the analyst has a success rate of
Express News | Keros Therapeutics Inc : Oppenheimer Initiates Coverage With Outperform Rating; Target Price $102
Keros Therapeutics Initiated at Outperform by Oppenheimer
Keros Therapeutics Initiated at Outperform by Oppenheimer
Oppenheimer Initiates Coverage On Keros Therapeutics With Outperform Rating, Announces Price Target of $102
Oppenheimer analyst Andreas Argyrides initiates coverage on Keros Therapeutics (NASDAQ:KROS) with a Outperform rating and announces Price Target of $102.
Truist Financial Initiates Keros Therapeutics(KROS.US) With Buy Rating
Truist Financial analyst Richard Newitter initiates coverage on $Keros Therapeutics(KROS.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 58.2% and a total average
Truist Securities Maintains Buy on Keros Therapeutics, Maintains $100 Price Target
Truist Securities analyst Srikripa Devarakonda maintains Keros Therapeutics (NASDAQ:KROS) with a Buy and maintains $100 price target.
A Quick Look at Today's Ratings for Keros Therapeutics(KROS.US), With a Forecast Between $80 to $100
On Jun 18, major Wall Street analysts update their ratings for $Keros Therapeutics(KROS.US)$, with price targets ranging from $80 to $100.BofA Securities analyst Jason Zemansky initiates coverage with
Keros Therapeutics Names Chief Executive Officer Jasbir Seehra as Board Chair
Keros Therapeutics (KROS) said late Monday that Chief Executive Officer Jasbir Seehra will take over as board chair from July 1. The company said Carl Gordon, the current chair, will remain an "active
Keros Therapeutics Names Seehra as Chair; Rovaldi to Be President
By Matt Walker Keros Therapeutics' board appointed Chief Executive Jasbir Seehra as chair of the board, effective July 1. Seehra would succeed Carl Gordon, who would remain a board member, the compa
Express News | Keros Therapeutics:Filed Prospectus Supplement to Co's Shelf Registration Statement for Issuance & Sale of up to $350 Mln Shares of Common Stock
Keros Therapeutics Rovaldi Will Also Continue Serving as Oper Chief >KROS
Keros Therapeutics Rovaldi Will Also Continue Serving as Oper Chief >KROS
Express News | Keros Therapeutics Inc: Christopher Rovaldi Has Been Promoted to President, Effective July 1, 2024
Express News | Keros Therapeutics Inc - Appointed Jasbir S. Seehra, Ph.d., Chief Executive Officer, as Chair of Board, Effective July 1, 2024.
Keros Therapeutics Seehra Will Succeed Current Chair Carl L. Gordo Effective July 1
Keros Therapeutics Seehra Will Succeed Current Chair Carl L. Gordo Effective July 1
Express News | Keros Therapeutics Announces Leadership Updates
Keros Therapeutics Presented Additional Data From Its Two Ongoing Phase 2 Trials Of Elritercept (KER-050), For Very Low-, Low-, Or Intermediate-Risk Myelodysplastic Syndromes And Myelofibrosis
Elritercept continued to demonstrate a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion burden.Durable clinical responses were asso
Keros Therapeutics Presents Clinical Data From Its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association
Durable clinical responses were associated with improvements in patient-reported measures of fatigue.
Catalyst Watch: HP Enterprise Event, Walmart+ Week, Pure Storage Buzz, and Triple-witching Volatility